Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

June 4, 2016
Hossein Borghaei, DO

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the phase III CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non—small cell lung cancer (NSCLC).

Patients enrolled on the CheckMate-017 study were diagnosed with squamous NSCLC, while those enrolled in the CheckMate-057 study had nonsquamous NSCLC, Borghaei explains. Two-year results showed that nivolumab significantly improved overall survival compared with docetaxel in both studies. This demonstrates that, in the second-line setting, the single-agent has a long-term benefit in these patients.

Additional cytokine analyses that coincide with these data show that patients who harbor cytokine expression will generally have a more durable response with nivolumab, he adds.

<<<

View more from the 2016 ASCO Annual Meeting


x